Theglucagon-likepeptide-1receptor(GLP1R) is a G protein-coupledreceptor(GPCR) found on beta cells of the pancreas and on neurons of the brain. It is involved in the control of blood sugar level by enhancing insulin secretion. In humans it is synthesised by the gene GLP1R, which is present on chromosome 6. [5][6] It is a member of theglucagonreceptorfamily of GPCRs. [7] GLP1R is ...
SummaryGlucagon-likepeptide-1 (GLP-1)receptoragonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity.
Michael Krashes discussesglucagon-likepeptide-1receptors, their physiological role in glucose metabolism and the mode of action of their agonists that are used to treat obesity and were later shown to promote weight loss.
GLP-1 —glucagon-likepeptide-1 — is an incretin hormone. The GLP-1receptoragonist drug class mimics it pharmacologically. This article covers GLP-1 hormone biology, how the drug class works, what's FDA-approved as of April 2026, and the GLP-1 pathway genetics including GLP1R, FTO, and MC4R.
Furthermore, visual representations like the one above help us fully grasp the concept of Receptor For Glucagon Like Peptide.
Abstract The unprecedented clinical success ofglucagon-likepeptide-1 (GLP-1)receptoragonists has transformed the therapeutic landscape for obesity, diabetes, and cardiometabolic disease, while simultaneously reshaping long-standing perceptions ofpeptide-based therapeutics as biologically compelling but pharmacologically impractical.
GLP-1receptoragonists (glucagon-likepeptide-1receptoragonists) and GIP agonists (glucose-dependent insulinotropic polypeptide agonists) are both medicines that mimic the effects of incretin hormones, which are gut-derived hormones that stimulate insulin release after eating. GLP-1receptoragonists and GIP agonists are called incretin ...
